INOMAX® and your baby
INOMAX (also known as inhaled nitric oxide) is an inhaled drug that is approved by the U.S. Food and Drug Administration (FDA) for treating Hypoxic Respiratory Failure (HRF) in newborns greater than 34 weeks gestational age. HRF means that your newborn isn’t getting enough oxygen into his or her blood. Newborns with this form of respiratory failure are unable to breathe on their own and have high blood pressure in the blood vessels of their lungs, which is known as pulmonary hypertension.
How does INOMAX® treat hypoxic respiratory failure (HRF)?
When INOMAX is given to your newborn, it is mixed with oxygen in a breathing device called a ventilator. The drug relaxes the blood vessels so blood flow improves. This allows more oxygen to be picked up by the bloodstream and improves oxygen levels in your infant’s blood.
Are there other benefits?
The use of INOMAX in newborns with hypoxic respiratory failure may also reduce the need for a procedure called extracorporeal membrane oxygenation (ECMO). ECMO requires surgery to remove blood from the baby’s body and flow it through a machine that adds oxygen back into the blood and then returns it to the body.
What about risks and side effects?
As with any treatment, the use of INOMAX has some risks. These include, but are not limited to:
- Methemoglobinemia (reduced capacity of the blood to carry oxygen)
- Increased levels of nitrogen dioxide (nitric oxide byproduct) leading to lung damage
- Lowered blood oxygen after abrupt discontinuation
- Pulmonary edema (wet lungs) in patients with existing heart failure
- Hypotension (low blood pressure)
You may also read our Full Prescribing Information.
If you have more questions about INOMAX, please ask your healthcare professional.